Clinical Chem Therapeutic Drug Monitoring
To understand the clinical importance of drug monitoring
To outline the possible analytical issues in therapeutic drug monitoring
route of administration
rate of absorption
drug distribution within the body
rate of elimination
a drug must be at an appropriate concentration at its site of action
maximum therapeutic benefit
bioavailability - the fraction of initial administered dose of the drug that reaches its intended site of action or the systemic circulation
different routes of drug administration
different characteristics that affect the circulating drug concentrations
intravenous → most direct and effects + bioavailability is 100%
others: intramuscular, subcutaneous, transcutaneous oral administration; inhalation; rectal delivery
bioavailability is generally lower than 100%
drug absorption - transportation of the unmetabolised drug from the site of administration to the body circulatory system
mechanisms of drug absorption:
passive diffusion
carrier-mediated membrane transport
nonspecific drug transporters
gastrointestinal drug absorption
dependent on:
dissociation of the drug from its administered form
solubility of the drug in gastrointestinal fluid
its diffusion across the gastrointestinal membrane
tablets/capsules or liquid form?
weak acids or weak bases?
passive diffusion or active transport?
net movement of a drug from gastrointestinal lumen into systemic circulation
mainly by passive diffusion at gastrointestinal epithelium
in stomach:
orally administered drug must encounter the low pH in gastric juice and digestive enzymes
thick mucous layer and short transit time
limit drug absorption
determine drug formulation
in intestines:
overcome numerous digestive enzymes
largest surface area for absorption
membranes are more permeable
influenced by gastric emptying time, microflora in the intestinal tract and intestinal transit time
most drugs are absorbed in a predictable manner among healthy people
absorbance rate can be altered by
changes in intestinal motility
pH
inflammation
coadministration of certain foods or drugs
age, pregnancy or other pathologic conditions
transfer of the unmetabolised drug from one location in the body to another after absorption
drug dynamics - only free or unbound fraction interacts with its site of action & produces biologic responses
free fraction of circulating drug diffuses out of the vasculature into interstitial and intracellular spaces
relative proportion of drug between circulation and tissues
protein binding is influenced by:
protein concentration
pH
metabolic abnormalities
presence of other chemicals
drug distribution is impacted by:
blood perfusion
blood & tissue binding proteins
regional pH
permeability of cell membranes
body water composition
fat composition
diseases
drug elimination - irreversible removal of an administered drug from the body, or from the plasma/blood, via either
excretion of the unmetabolized drug in its intact form through renal, biliary, pulmonary, salivary or milk excretion
metabolism followed by excretion
hydrophilic drugs - directly excreted by kidneys
hydrophobic drugs - metabolic biotransformation before excretion
metabolism - mainly in liver
excretion - mainly in kidneys
significant dysfunction → accumulation of the drug or its metabolites in toxic concentrations
Phase I
oxidation, reduction & hydrolysis
catalysed by hepatic microsomal enzymes
cytochrome P450
CY3A4 responsible >50% of existing drugs
various classes: opioids, immunosuppressants, antihistamines, benzodiazepines
Phase II
covalent binding of polar group to non-polar drug molecules → become water-soluble
allow renal or biliary excretion
polar adjuncts: amino acids, glucuronic acid, glutathione, acetate & sulfate
example: glucuronidation pathway catalysed by UDP-glucuronosyltransferase enzyme
renal excretion
free fraction of the drugs or its metabolites is filtered in the kidneys, and excreted in the urine
drug elimination rate directly relates to glomerular filtration rate
biliary excretion
liver actively secretes ionised drugs into bile to be:
eliminated in faeces; or
reabsorbed as part of the enterohepatic cycle
activity of a drug in the body as influenced by absorption (A), distribution (D), metabolism (M), and excretion (E) of the drug
study of the disposition of a drug after its delivery to an organism
how the body interacts with administered drugs for the entire duration of exposure
half-life - amount of time for serum drug concentrations to decrease by 50%
most drugs are delivered on a scheduled basis (e.g., once every 8 hours)
blood drug concentrations oscillate between the peak drug concentration (maximum) and trough drug concentration (minimum)
multiple-dosage regimen
5-7 doses are required before reaching a steady-state
To understand the clinical importance of drug monitoring
To outline the possible analytical issues in therapeutic drug monitoring
route of administration
rate of absorption
drug distribution within the body
rate of elimination
a drug must be at an appropriate concentration at its site of action
maximum therapeutic benefit
bioavailability - the fraction of initial administered dose of the drug that reaches its intended site of action or the systemic circulation
different routes of drug administration
different characteristics that affect the circulating drug concentrations
intravenous → most direct and effects + bioavailability is 100%
others: intramuscular, subcutaneous, transcutaneous oral administration; inhalation; rectal delivery
bioavailability is generally lower than 100%
drug absorption - transportation of the unmetabolised drug from the site of administration to the body circulatory system
mechanisms of drug absorption:
passive diffusion
carrier-mediated membrane transport
nonspecific drug transporters
gastrointestinal drug absorption
dependent on:
dissociation of the drug from its administered form
solubility of the drug in gastrointestinal fluid
its diffusion across the gastrointestinal membrane
tablets/capsules or liquid form?
weak acids or weak bases?
passive diffusion or active transport?
net movement of a drug from gastrointestinal lumen into systemic circulation
mainly by passive diffusion at gastrointestinal epithelium
in stomach:
orally administered drug must encounter the low pH in gastric juice and digestive enzymes
thick mucous layer and short transit time
limit drug absorption
determine drug formulation
in intestines:
overcome numerous digestive enzymes
largest surface area for absorption
membranes are more permeable
influenced by gastric emptying time, microflora in the intestinal tract and intestinal transit time
most drugs are absorbed in a predictable manner among healthy people
absorbance rate can be altered by
changes in intestinal motility
pH
inflammation
coadministration of certain foods or drugs
age, pregnancy or other pathologic conditions
transfer of the unmetabolised drug from one location in the body to another after absorption
drug dynamics - only free or unbound fraction interacts with its site of action & produces biologic responses
free fraction of circulating drug diffuses out of the vasculature into interstitial and intracellular spaces
relative proportion of drug between circulation and tissues
protein binding is influenced by:
protein concentration
pH
metabolic abnormalities
presence of other chemicals
drug distribution is impacted by:
blood perfusion
blood & tissue binding proteins
regional pH
permeability of cell membranes
body water composition
fat composition
diseases
drug elimination - irreversible removal of an administered drug from the body, or from the plasma/blood, via either
excretion of the unmetabolized drug in its intact form through renal, biliary, pulmonary, salivary or milk excretion
metabolism followed by excretion
hydrophilic drugs - directly excreted by kidneys
hydrophobic drugs - metabolic biotransformation before excretion
metabolism - mainly in liver
excretion - mainly in kidneys
significant dysfunction → accumulation of the drug or its metabolites in toxic concentrations
Phase I
oxidation, reduction & hydrolysis
catalysed by hepatic microsomal enzymes
cytochrome P450
CY3A4 responsible >50% of existing drugs
various classes: opioids, immunosuppressants, antihistamines, benzodiazepines
Phase II
covalent binding of polar group to non-polar drug molecules → become water-soluble
allow renal or biliary excretion
polar adjuncts: amino acids, glucuronic acid, glutathione, acetate & sulfate
example: glucuronidation pathway catalysed by UDP-glucuronosyltransferase enzyme
renal excretion
free fraction of the drugs or its metabolites is filtered in the kidneys, and excreted in the urine
drug elimination rate directly relates to glomerular filtration rate
biliary excretion
liver actively secretes ionised drugs into bile to be:
eliminated in faeces; or
reabsorbed as part of the enterohepatic cycle
activity of a drug in the body as influenced by absorption (A), distribution (D), metabolism (M), and excretion (E) of the drug
study of the disposition of a drug after its delivery to an organism
how the body interacts with administered drugs for the entire duration of exposure
half-life - amount of time for serum drug concentrations to decrease by 50%
most drugs are delivered on a scheduled basis (e.g., once every 8 hours)
blood drug concentrations oscillate between the peak drug concentration (maximum) and trough drug concentration (minimum)
multiple-dosage regimen
5-7 doses are required before reaching a steady-state